Pharvaris released positive long-term data for its oral bradykinin B2 receptor antagonist, deucrictibant, at the 2025 AAAAI/WAO Joint Congress. The data highlighted sustained efficacy and safety in both prophylactic and on-demand treatment of Hereditary Angioedema (HAE) from extension studies of previous Phase 2 trials. The findings demonstrate the potential of deucrictibant to address unmet needs in the HAE community.
These findings are important for HAE patients, who often experience debilitating and unpredictable swelling attacks. Current treatment options can be inconvenient, requiring injections or infusions. A safe and effective oral therapy like deucrictibant could significantly improve patients’ quality of life by offering convenient, at-home treatment and prevention, reducing the fear and limitations imposed by HAE. The observed improvements in quality-of-life metrics related to functioning and fear/shame underscore the potential impact of deucrictibant on patients’ daily lives.
The CHAPTER-1 open-label extension study showed participants maintained a reduced monthly HAE attack rate for at least 1.5 years with a median proportion of symptom days at zero. All participants in the CHAPTER-1 OLE who had reached week 62 reported improved health-related quality of life. In the RAPIDe-2 extension study, data from seven upper airway attacks, including laryngeal attacks, revealed a median time to symptom relief of 0.9 hours. Both extension studies confirmed the drug’s tolerability with no new safety signals.
The positive long-term data strengthens Pharvaris’ position in developing an oral HAE therapy. The results support the ongoing Phase 3 trials for both prophylactic and on-demand deucrictibant and increase the likelihood of a successful regulatory submission. If approved, deucrictibant could offer a valuable new treatment option for HAE patients, potentially shifting the treatment paradigm towards oral therapies and improving disease management.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
